Leerink Partners Raises Moderna Price Target but Maintains Underperform Rating

Key Facts

Amid shifting dynamics in the post-pandemic biotech sector, Leerink Partners has adjusted its outlook on Moderna. According to reports, the firm raised its price target for the stock from $21 to $24. However, the analysts maintained an 'Underperform' rating, signaling continued caution as the company grapples with quarterly losses and broader market pressure on its core product lines.

This minor target adjustment occurs as Moderna faces stiff competition and sector-wide headwinds; for context, peer Pfizer has seen its shares decline by approximately 1.5% over the past month per market data. Analysts cited by Bloomberg indicate that the vaccine industry is struggling with a transition away from pandemic-era revenue levels, leading to a consensus of lowered earnings expectations across the mRNA technology space.